Redeye provides a research update following ExpreS2ion’s Q3 report and webcast. Lower-than-expected grant income resulted in revenues and EBIT below our estimates, while the underlying cash burn was broadly in line with expectations. Operationally, the Phase I study of ES2B-C001 is now fully enrolled with a continued clean safety profile, and management outlined a partner-funded Phase II study in first-line HER2-positive breast cancer, although the primary readout has been moved to Q1 2027. Having updated our model for the Q3 outcome and the completed TO 13 programme, we reiterate our fair value of SEK4 per share.
LÄS MER